|
This is a healthcare, not a
healthcure, website. It's about all the things you can do to keep
yourself and your community healthy. We will try to combine
common sense with current authoritative data.
This is how you stay healthy, not
how you get healthy. Some of it is about what you do (get thin,
stop smoking, consume vegetables, run for 20 minutes). But a lot
is what we must do to our politicians (beef up disease prevention
centers, cut water and air pollution, use airwaves for a host of public
health information to enable our citizenry, target dollars at bigest
disease conditions, expand charters of lower-rank and lower-paid health
professionals).
224. -new- Bio
for Bees: Bee Plaque
For several years now an
illness has been afoot that has devastated bee colonies. “Researchers are scrambling to find
the cause of the ailment, called Colony Collapse Disorder.” (Associated
Press, February 12, 2007). “Reports of unusual colony deaths have come
from at least 22 states. Some affected commercial beekeepers — who often
keep thousands of colonies — have reported losing more than 50 percent of
their bees. A colony can have roughly 20,000 bees in the winter, and up to
60,000 in the summer.” “Scientists
at Penn State, the University of Montana and the U.S. Department of Agriculture
are among the quickly growing group of researchers and industry officials
trying to solve the mystery” “Cox-Foster said an analysis of dissected
bees turned up an alarmingly high number of foreign fungi, bacteria and other
organisms and weakened immune systems.”
It should
be noted, however, that waves of disease have periodically stricken bee
populations since colonial times. It is possible this is just another one of those serious but predictable
outbreaks. Beekeepers lost 37% of their hives in 2008, and 31% in 2007. “Enter Beeologics, a Miami Biotech startup that
aims to create vaccines for all viruses that could lead to CCD.” Fortune Small Business, March 2009,
p.27. “Ilan Sela, 71, an Israeli
expert on sequencing the genome of bee viruses” is involved. “Jeff Pettis, head
of the USDA’s
Bee Research Laboratory, is cautiously enthusiastic about Remebee’s
potential.” This is their first
vaccine to be sold at $2 a does in summer 2009.
(06-03-09)
223. Cancer: Get It Way Early with Statistics
“The US spends billions of dollars to save these late-stage patients, trying to devise better drugs and chemotherapies that might kill a cancer at its strongest. This cure-driven approach has dominated the research since Richard Nixon declared war on the disease in 1971. But it has yielded meager results: The overall cancer mortality rate in the US has fallen by a scant 8 percent since 1975. (Heart disease deaths, by comparison, have dropped by nearly 60 percent in that period.) We are so consumed by the quest to save the 566,000 that we overlook the far more staggering statistic at the other side of the survival curve: More than a third of all Americans—some 120 million people—will be diagnosed with cancer sometime in their lives. Their illness may be invisible now, but it's out there. And that presents a great, and largely unexamined, opportunity: Find and treat their cancers early and that 566,000 figure will shrink.” Wired, “Why Early Detection Is the Best Way to Beat Cancer,” December 22, 2008. “This new approach treats diagnosis as an algorithm, a sequence of calculations that can detect or predict cancer years before it betrays symptoms. It starts with a statistical screening to identify people, like Rosenthal, who have a genetically greater risk for disease. A regular blood test follows, one primed to look for telltale proteins, or biomarkers, correlated to specific cancers. A positive result prompts an imaging test to eliminate false positives or isolate a tumor. The process is methodical, mathematical, and much more likely to find cancer than current diagnostic procedures.” “In 2004, he (Listwin) created the Canary Foundation, a research group with the single goal of bringing a battery of screening tests to patients and their doctors by 2015, starting with ovarian cancer and moving on to pancreatic, lung, and prostate. Listwin likes to explain the Canary approach with PowerPoint, and every presentation starts with a slide of the survival curve for cancer. Pointing to the 90 percent, he makes this simple observation: When we see cancer early, we have a chance to fight it.”
Quite a body of research is growing up in which mathematics is being put to work on cancer detection. See “Can Math Cure Cancer?” Forbes, October 27, 2008, pp.74-76. Kristin Rae Swanson of the Unversity of Washington has “created a software program that uses data from magnetic resonance imaging scans to simulate how fast a patient’s brain tumor is likely to spread.” “Swanson’s” equation “bears a certain resemblance to the Fourier heat equation.” (03-04-09)
222.Doctor
Restaurants
“A new type of eatery called a ‘doctor’s restaurant’ … is becoming
popular in Japan. Such restaurants provide menus that have been
certified by physicians from a medical standpoint” (Trends In Japan, 8
August 2008). “One such establishment is Tokyo Food Theater 5+1,
located in Tokyo’s Akihabara district. Medical specialists were
involved in planning this restaurant’s menu. The ‘anti-aging and
beautiful skin’ course, for example, was developed under the
supervision of Professor Shirasawa Takuji, who teaches a course on
anti-aging medicine at Juntendo University, Graduate School of
Medicine.” “Osaka, meanwhile, is home to a restaurant called
Chishoku Shunsai ETSU, whose cuisine is designed specifically to be
safe and healthy for people with diabetes.” “Mikuni Minceur is
located inside the Yotsuya Medical Cube in Tokyo’s Yotsuya district,
and it serves mainly French food under the concept of providing
customers with ‘beautiful, delicious, and healthy cuisine.’ This
restaurant's cuisine minceur features a variety of tastes contained
within low-fat foods.” (11/5/08)
221. Getting Water
A goodly portion of the world’s population does not have
access to germ-free water. Huge problems ensue for people in
underdeveloped nations. Mikkel Vestergaard of Denmark, who spent
a goodly amount of time in Nigeria, has, as a result, devised the
LifeStraw, “a personal, portable water purifier that eliminates
virtually all waterborne bacteria and most viruses responsible for
causing diarrheal diseases.” Today he heads a family firm in
Lausanne, Switzerland, Vestergaard
Frandsen, which makes the LifeStraw. It uses textile and
iodine filters, and carbon to sift out the taste of iodine.
Founded as a maker of work clothing, it shifted into 1992 to relief-aid
products. It also manufactures PermaNet, an insecticide treated
mosquito net. (9/24/08)
220. Health Phone
Everybody makes a big deal out of all the schemes to
deliver us better health over the Internet, ranging from patient
information records to sundry ways of providing information about
diseases and sundry health conditions. The trouble is that most
of them are created by and designed for health nerds who are earning
their living in the health business. They’re not for
patients. In fact, the telephone is the best device for dealing
with live patients and helping them out, since the sickest are elderly
and not inclined to use computers.
Along comes Voxiva in Washington,
D.C. Paul Meyer, its chairman, has a “long history of pulling off
projects in challenging locations: Albania, Guinea, India” (Forbes,
June 30, 2008, pp. 58-60). “Meyer created a communications system
that works on any telephone network and can be accessed on any mobile
handset, PC or landline phone using voice messages, e-mail or SMS
text.” “Last year the company grew 58% and was cash flow positive
in the fourth quarter. Today Voxiva has 120 employees, clients in
15 countries, and 60 projects underway.” (9/10/08)
219. Hospital Towns
“What happens when a clinic takes over a metropolis?” (Economist,
February 23, 2008, p.44). “A select few cities have entered the
era of the mega-hospital. The most dramatic are Rochester, a
medium-sized city where Mayo has long been a star business, and
Cleveland, Ohio, a rustbelt city that has seen its hospitals boom and
one, the Cleveland Clinic, become a new economic force. Each
hospital is a behemoth: Mayo’s revenues in 2006 totalled $6.3
billion, Cleveland’s $4.4 billion.” “The Cleveland Clinic is America’s
best heart hospital; Mayo tops the rankings for neurology, digestive
disorders and endocrinology.” Their systems are huge, and their main
campuses are larger than the Pentagon. “Cleveland’s 37,350
employees make it Ohio’s second-largest private employer in 2006, after
Wal-Mart. Mayo is Minnesota’s biggest private employer.”
Both have become big destinations for health tourists. Both have
branched out in various ways to other locales, expanding their
revenues. However, this article really does not evaluate what
happens to the community when it is host to a health colossus. We
do not even know if it has a positive, neutral, or negative effect on
the city’s health. (7/30/08)
218. Cortisol and Chronic
Fatigue Syndrome
“The researchers, writing online in The Journal of Clinical
Endocrinology and Metabolism, said the low levels of the hormone,
cortisol, might play a role in the severe fatigue found in many
patients with the syndrome” (New York Times, January 29, 2008,
p. D6). “We were surprised that the effect was limited to women,”
Dr. Reeves said in an email message, “and this may help to explain the
higher prevalence of C.F.S. in women.” We suspect the cortisol
variation is a symptom of the disease condition, rather than a
causative factor. Nonetheless, it is still heartening to get any
faint hint as to what goes on with this elusive disease. See
“Attenuated Morning Salivary Cortisol Concentrations in a
Population-based Study of Persons with Chronic Fatigue Syndrome and
Well Controls” (JCEM, December 26, 2007). (4/16/08)
Update: Roots of Chronic Fatigue
Syndrome
Scientists have new hunches as to the origins of chronic fatigue
syndrome or myalgic encephalomyelitis (ME). It may have its roots
in genetics. ME Research
UK and Irish ME Trust had a recent
meeting where new findings emerged. Jonathan Kerr of St.
George’s University in London said he and his colleagues have
identified 35 genes that are expressed differently in CFS
sufferers. Julia Newton of Newcastle University found that the
automatic nervous system may be askew in many acute sufferers: those
taking exercise suffer from acid build-up in the muscles. It’s
thought that drugs that help maintain blood flow could make up for the
erratic nervous systems. There is some thought that CFS may come
at the tail end of a period of infectious disease in those with a
predisposition to such fatigue. (10/8/08)
217. Garlic's
Magic Gas
Garlic, it seems, stimulates the body’s generation of
hydrogen sulfide—and that turns out to be a good thing. See
“Unlocking the Benefits of Garlic, “ New York Times, October
15, 2007. “In the latest study, performed at the University of
Alabama at Birmingham, researchers extracted juice from supermarket
garlic and added small amounts to human red blood cells. The
cells immediately began emitting hydrogen sulfide, the scientists
found. The power to boost hydrogen sulfide production may help
explain why a garlic-rich diet appears to protect against various
cancers, including breast, prostate and colon cancer, say the study
authors. Higher hydrogen sulfide might also protect the heart,
according to other experts.” As it turns out, one needs to eat 5
to 8 cloves a day to get a bang. Further, one should let the
garlic sit 15 minutes after crushing, before using it in cooking.
(4/2/08)
216. Blood
Pressure: Containing the Gorge
Another instance where we don’t know which is the
chicken and which is the egg. People with lower blood pressure
are happier, and visa versa, but who knows what causes what.
“Researchers at the University of Warwick have found a direct
connection between a nation’s overall happiness and its citizens’ blood
pressure problems. Sweden, Denmark and the UK come top of this
blood pressure based happiness league while Germany, Portugal and
Finland come bottom.” “Happy countries have fewer blood-pressure
problems. Mental health in each country, they show, is also
inversely correlated with its rate of hypertension. The study
ranks countries in this order: Sweden, Denmark, UK, Netherlands,
Ireland, France, Luxembourg, Spain, Greece, Italy, Belgium, Austria,
Finland, Germany, Portugal” (Press Release, University of Warwick, 18
Feb. 2007). (1/30/08)
215. Dutch
Health Insurance
The Dutch have come up with a scheme where everybody gets
health insurance, but private health insurance carriers provide the
coverage. See “In Holland, Some See New Model for U.S.
Health-Care System,” Wall Street Journal, September 6, 2007,
pp. A1 and A14. “Since a new system took effect here last year,
cost growth is projected to fall this year to abot 3% after inflation
from 4.5% in 2006. Waiting lists are shrinking, and private
health insurers are coming up with innovative ways to care for the
sick.” Everybody gets health insurance; insurers must
accept everybody who applied; the government provides aid to those who
cannot afford premiums through a tax on the rich. Menzi’s
has opened primary care centers of its own to lower costs; UVIT gives
discount vouchers to those using low cholesterol dairy products and
offers other incentives for consumers leading healthy lives. This
is along the lines of Alain Enthoven’s managed
competition. The government also provides ‘risk equalization’
payments to companies for taking on the elderly and chronic patients
with certain conditions. The changeover has apparently gone rather
smoothly with premiums lower than predicted. Generic drug prices
have also come down due to negotiations by the government. The
insurers, however, have had some profit difficulties, and it remains to
be seen whether they can get hospitals to cut costs to help shrink
their burden.
As in many things, healthcare innovation appears to be taking place
outside the main developed nations (U.S., Germany, Japan, etc.).
We have previously pointed to Finland
as the country that has shown the most dramatic gains from activist
public health measures. (11/28/07)
214. Super
Testing
Akonni Biosystems in
Maryland is working on a gadget that will test for everything on the
cheap. It will look for every kind of infection, and it won’t
cost an arm and a leg as does the present battery of tests for
diseases. “Daitch calls his tool TruDiagnosis. It combines
advances in microfluidics (miniaturized pumps and channels),
microarrays (micron-sized sensors affixed to a chip), and engineering
into what could be the ultimate medical gadget: a handheld device that,
using a small sample of blood or spit, reveals in mere minutes every
pathogen inside the body. It would work in hospitals, in labs, in
the field, perhaps even in homes. TruDiagnosis is Akonni’s twist
on so-called molecular diagnostics, the promising discipline that
detects the presence of a bacteria or virus when only a few molecules
of DNA, protein, or other biomarkers are present.” “Akonni … is
going low-cost, high-volume. The TruDiagnosis system has two
parts: the credit card sized array, which can be tailored to detect
combinations of diseases or strains of a particular disease, and the
device that processes and reads the array.”
“Right now, Akonni’s reader is about the size of a Nintendo Wii
console. Daitch is producing a prototype for a handheld device
that looks very much like an iPod. But making it work is a
challenge more worthy of the iPhone—cramming three functions onto one
tidy package” (Wired,
July 24, 2007). (11/14/07)
213. Mainstream
Botanical Drugs?
The FDA, for the first time, is looking at botanical drugs in a serious
way. “Some 250 botanical drugs have … been cleared to proceed to
clinical trials. See “Dueling Therapies: Is a shotgun better than
a silver bullet?” Wall Street Journal, March 2, 2007, p.
B1. On the Global Province we include an essay from one noted
researcher—“A Third
Arm for the First World”—suggesting to the FDA that botanical
alternatives be included in all drug trials, since the vast majority of
manufactured drugs show such an array of side effects. At least
the FDA has opened the door to useful botanical trials.
By and large, the results with botanicals have been spotty. “One
company that is aiming to beat the odds is Phynova, a small British
drug-research concern that has the green light from the FDA to test a
hepatitis botanical drug. The drug is a combination of four
different plants: the roots of the astragalus and the Chinese salvia
plants, the fruit of the schisandra plant, and milk thistle. The
hope is that they will all work synergistically to combat the symptoms
of chronic hepatitis.” We had a doctor in the Far East look over
the ingredients; he replies: “Good combo, probably with the latter two
ingredients best.” (10/31/07)
212. Counter
“Sicko”
“Average lifespan has increased 30 years over the past century—mostly
due to commercially developed vaccines,” says Paul Offit, chief of
infectious diseases at Children’s Hospital in Philadelphia (“Sick
Propaganda,” Wall Street Journal, July 13, 2007, p. A13).
Nine vaccines—“which save about eight million lives a year”—were made
by Maurice Hilleman
of Merck. Offit is right about vaccines, of course, which he uses
to put down Michael Moore’s Sicko, which castigates the
pharmaceuticals. Unfortunately it’s a false argument. The
pharmaceuticals and the healthcare system are peddling treatments
galore that are useless or worse, with responsible estimates suggesting
that 1/3 of healthcare procedures simply should not be done. As Moore
makes clear, this is wasteful and horribly expensive. Vaccines
and preventive care, which the hopeless Moore does not dwell on, must
become the order of the day. (9/19/07)
211.
Training Rural Doctors
“Now, a company called Haoyisheng.com Inc. … has set up outlets in
remote villages and small cities like Mile (pronounced Meel-eh), where
local doctors attend video classes in essential matters of diagnosis
and care. So far, Haoyisheng.com has outfitted 6,000 classrooms
in eight provinces, with the blessing of the Chinese government, which
has brought in more than 120,000 doctors to educate” (Wall Street
Journal, July 10, 2007, p. B1). Local doctors see videos that
deal with the kind of clinical situations that are expected to crop up
regularly. Distance learning courses such as these are cheap and
practical, but the trainees do suffer from lack of one-on-one contact
with a medical professional.
“In
Mile, the fee for three years of classes is 3,400 yuan (about $448),
plus 400 yuan for books. Haoyisheng receives about 1,200 yuan per
student from the government. The company, which has training
programs in urban areas as well as short-term courses on topics such as
emergency medicine, says it had a profit of $1 million last year on
revenue of $9 million.” (9/12/07)
210.
Blood Pressure Vaccine? Brain Pressure?
There are reports of a new blood-pressure vaccine “based on a protein
found in the sea creature the limpet. The new vaccine consists of
a course of three injections followed by a booster every six months;
the vaccine attacks a hormone called angiotensin which is produced by
the liver and is the main culprit in raising blood pressure.” (Pharmaceutical
News, 15 May 2007). Developed by a firm called Protherics, there are already
many questions about its efficacy. A Swiss firm, Cytos Biotechnology, is also reported
to be developing a similar product.
Interestingly, variant theories are now
appearing as to what causes high blood pressure. Some UK scientists
trace it to the brain, instead of the heart or blood vessels. We
suspect this will produce entirely new treatments that will affect
other parts of the causal chain. The University of Bristol,
which is spawning much innovative research reports:
Professor Julian
Paton and his colleagues Hidefumi Waki and Sergey Kasparov, have
discovered a new protein, JAM-1 (junctional adhesion molecule-1), which
is located in the walls of blood vessels in the brain.
JAM-1 traps
white blood cells called leukocytes which, once trapped, can cause
inflammation and may obstruct blood flow, resulting in poor oxygen
supply to the brain. This has led to the novel idea that high
blood pressure—hypertension—is an inflammatory vascular disease of the
brain.
An
article about this hypothesis appears in the June 2007 issue of Hypertension.
(8/22/07)
209.
Try a Little Tenderness
The doctors have all sorts of wretched, leech sucking ways to make you
think you are getting better. If it does not hurt, it must not be
doing you any good. One of the mouthwash companies once improved
the flavor of its brand, and sales went into the tank. People
figured that if it tasted good, it must not be going you any
good. So the brand managers made sure, once again, that it tasted
awful. Now imagine our substitute for antibiotics—honey.
How, some will ask, could honey be good for what ails you?
Honey was
commonly used in medicine before antibiotics became widespread. It is
still used in the Antipodes; an Australian company makes a product
called Medihoney for medicinal use. This formulation is a certified
medicine in Europe, but has not been much used there because doctors
developed a taste for prescribing conventional antibiotics.
Research in
Australia and New Zealand suggests that honey heals because it attacks
bacteria in several different ways at once. Because honey is composed
of saturated sugars, it sucks up water, depriving bacteria of the
liquid they need to survive and multiply. As bees make honey they
secrete glucoseoxidase, an enzyme that releases the bleach hydrogen
peroxide when it comes into contact with wound liquids. The low-level
but frequent release of this chemical ensures regular anti-bacterial
washes of the wound. (Economist, 26 April 1007)
Importantly,
honey seems to work against some of the deadly germs that are resistant
to antibiotics and that one finds in hospitals. (8/8/07)
Update: Honey for Coughs
Every time we turn around we discover new uncanny applications for
honey that touches on a variety of complaints. The Penn State College
of Medicine has discovered that it is a good thing to stem
children’s uncontrollable coughing, better in fact than many standard
cough medicines. “The study found that a small dose of buckwheat
honey given before bedtime provided better relief of nighttime cough
and sleep difficulty in children than no treatment or dextromethorphan
(DM), a cough suppressant found in many over-the-counter cold
medications.” See “Effect
of Honey, Dextromethorphan, and No Treatment on Nocturnal Cough and
Sleep Quality for Coughing Children and Their Parents,” Archives of
Pediatric and Adolescent Medicine, December 2007. (4/30/08)
208.
Britain
Health Productivity Reforms
The Labor government is trying to get its arms around National
Healthcare Costs and Quality. First off, it is paying its
hospitals in a different way. Before they got block grants based
on previous budgets. Now they get paid by transaction, and the
hope is that they will do more for their money. But, too, there
is a counterbalance to make sure they are not doing lots of unnecessary
procedures. That is, the status of General Practitioners has
risen, and they will be gatekeepers with a budget who pass on whether
patients really need this or that treatment. See the
Economist, March 3, 2007, p.58. It’s the latter problem that
particularly affects America, where it is estimated that perhaps 1/3 of
the medical procedures that are rendered are rather unnecessary.
We’re doing a whole mess of medicine that does not help the
patient, and often hurts. (8/1/07)
207.
Looking into Eyeglasses
Eyeglasses—and optometry—add up to one of the greatest scams in the
healthcare systems with gullible consumers paying $200 or more for a
pair of spectacles. Simple glasses should cost you $5, or $10 at
the worst. Sam’s, Wal-Mart’s warehouse discount unit, once
charged you $20 or so for 12 pairs, back before it got so heavily in
the jewelry and eyeglass business—and they had good frames to boot.
Now the average drugstore sells off-the-rack glasses with shoddy
frames for $15 a pair. The New York Times, May 5, 2007,
has done a credible job of looking at the problem in “Do-It-Yourself
Eyeglass Shopping on the Internet.” What it comes down to is that
you can find some wares on the Internet at better, if not fair, prices,
though it is still a fragmented, over-priced mess. “But a frame
that costs less than $25 to make in Italy can retail for at least $150
at an optical shop in the United States.” Zenni
Optical does seem to offer good bargains using China frames. Glassy Eyes reviews various
vendors—and tries to cut through the eyeglass scam. “Although the
frames carry fat profit margins, the real money for the retailer is in
the lenses. There the markup can be three to seven times the
wholesale price. Most single-vision lenses—those that are not
bifocals or the ‘progressive lenses,’ which are bifocals without the
line—are precast in large quantities and can cost about $1 to make.
The eyeglass dispenser just picks them out of a tray.”
The Times
does bring out of the closet one vital piece of information your
optometrist may not share with you. “The one crucial piece of
data most consumers are probably missing is the pupillary distance,
which is how close the eyes are to each other. That remains
fairly constant in adulthood, but it varies from one person to the
next.” “Any eye doctor or optician can provide the number.
It is against the law for an eye doctor to refuse to give you a
copy of your prescription. In most states, they are under no
obligation to provide the “P.D.” Some doctors, especially those
selling the eyeglasses, may refuse because they know that with that
number you can shop elsewhere. Just insist on it.” Insist
on it. (7/25/07)
206.
Stroke
Watch
“As of today, the Society for Vascular Surgery … is for the first time
recommending these three tests to screen for artery disease in many
people 55 years old and over” (Wall Street Journal, April 17,
2007, p. D2). They are: a carotid ultrasound to find fatty plaque
in neck arteries; ankle-brachial test to get at plaque in the legs and
throughout the body; and abdominal ultrasounds to see if the
aorta has a bulge or aneurysm. Some free offerings can be found
at www.vascularweb.org. A
high percentage of the nation’s strokes are attributed to carotid
blockages. (7/18/06)
205.
Coenzyme Q10
“Companies that sell Coenzyme Q10 say daily doses improve heart
function and increase energy levels. Scientific evidence on
Coenzyme Q10 is mixed, and physicians urge patients not to stop taking
conventional drugs” (Wall Street Journal, March 27, 2007, p.
D2). Scientists are clearly mixed about it, though they generally
seem to agree that it offers no harmful side effects. There has
been an issue as to quality—with samples sometimes not including
intense enough quantities of the supplement. Then too, one must
test to find products with high enough absorption rates. “For
effective therapy in patients with heart failure,” one is apparently
striving “for 2.5 to 3.5 micrograms of the coenzyme for every
milliliter of blood,” compared with the normal .8 customarily found
before treatment. Advocates think it adds energy to parts of the
body where high energy is required. A wider range of
applications is suggested in some articles. While the WSJ
urges readers not to discontinue other heart medications when using it,
some researchers suspect that statins, beta blockers, and blood
pressure drugs may cut its efficacy. (7/11/07)
204.
Happiness
Is Very Low Key
“Mental health and blood pressure are a better guide to happiness in
Europe than economic performance.” A study of 16 countries found
that people who regarded themselves as happy had lower blood pressure.
“People in Sweden, the Netherlands, Denmark, the UK and Ireland
had the fewest blood pressure problems, while those in Portugal,
Germany, Italy and Finland were among those with the most” (Financial
Times, March 3-4, 2007, p. 2). “It is now well established
that people in richer countries tend to be happier,” but high economic
growth rates do not necessarily correlate with happiness.
Economists studying happiness have had mixed success uncovering what
kinds of things produce people with a high sense of wellbeing.
(5/30/07)
203.
Doctors
Who Write
Abigal Zuger, a doctor herself, has written a very thin article about
“Doctors Who Wield the Pen to Heal the Profession,” New York Times,
May 15, 2007, p. D6. First off, we find that doctors who
write are mainly healing themselves, sensitive individuals who actually
have some guilt and remorse for the fact that they are made of mortal
clay and have committed some grievous errors along the way as they have
plied their trade. It is not altogether certain that their
writing, inspired as it is, really does much to change the profession,
which has structural flaws that are so deep that they will not submit
to the limited analysis of medical practitioners. She
particularly mentions two New Yorker writers, Atul Gawande and
Jerome Groopman, both best-selling stars of the moment, who are part of
the Harvard Medical/Mass General orbit. Gawande has written
convincingly about the venalities of the trade where habit and avarice
affect performance. Groopman has touched on many of the habits
and mental shortcuts that lead to poor diagnosis, something that even
led to poor treatment for him. One wishes that Zuger had dealt
with the raft of other fine medical writers such as Lewis Thomas of
Memorial Sloane Kettering,
Richard Selzer of Yale, and the incomparable Oliver Sacks—each
of whom is endowed with a special esthetic sense that takes their
writing to a higher plane. Consistently, incidentally, the best
writing in the New Yorker is about a health, probably
indicating that both its editors and readers are a bunch of
hypochondriacs. Henry Finder, its editorial director, is a
card-carrying health writer. (5/23/07)
202.
Anti-mottainai
Mottanai means ‘what a waste,’ and, more than ever, the Japanese are
eager to waste not. “Fruits and vegetables that are rejected for
sale because they are irregularly shaped or bruised are often thrown
away. Now, however, these otherwise perfectly good foods are
being used in purée form under the brand name
Nepurée.” See Trends in Japan, February 5,
2007. “Nepurée products are made from fruit or vegetables
that have been subjected to intense heat for a short time and then made
into puree form using centripetal force. The application of heat
brings out the sweetness that fruits and vegetables naturally contain,
and because no cutting instruments are used, the nutritional elements
are undamaged at the cellular level. The manufacturer Vegetech
Co. and its partner Kanto Orto Co. released products last year bearing
the message ‘the new shape of vegetables.’” (4/4/07)
201.
Tips Before You Go to the Hospital
“If your ailment doesn’t kill you, the hospital will.” As we said
in
“Hyper-Germs and the Power of Soap,” hospital infections have
gotten much more deadly and claim a considerable number of lives.
The
AARP gives some good suggestions on things you personally can do to
guard against infection:
-
Wash your hands frequently. And don’t be
shy about reminding doctors, nurses and aides to wash theirs.
-
People who smoke or are overweight are
more susceptible to infection, so try to quit and lose before surgery.
-
Wash with 4 percent chlorhexidine
antibiotic soap for several days before surgery.
-
Ask your doctor for a nasal swab test
for MRSA.
-
Be sure the doctor prescribes an
antibiotic for you before surgery.
-
Don’t allow the doctor to shave the
surgical site—tiny cuts from the razor can get infected. Use hair
clippers.
-
Ask friends and family to stay away if
they’re ill, and ask the doctor to limit the number of aides and
medical students in your room.
-
Call a nurse
promptly if IVs or catheters become loose or damaged; the sites should
be kept clean and dry. (3/21/07)
200.
China—Drugs, Hospitals, Tests,
Fancy Procedures
The broken healthcare system in China—a great worry for the political
leadership—exposes even more dramatically the conflict between the
incentives built into the healthcare system and cost effective, health
effective healthcare. This is the same tension we discussed
previously in respect to Virgina Mason Hospital in Seattle. See
“In China, Prevention Pits Doctor Against System,” Wall Street
Journal, January 16, 2007, pp.A1 and A18. The Chinese have
lost the safety net offered in more doctrinaire times of public
services and healthcare: now citizens must pay stiff fees without the
aid of healthcare insurance. Doctors and hospitals are rewarded
for procedures and prescriptions, so large chunks of unaffordable,
expensive healthcare are inflicted on patients without particular
regard to outcome or cost effectiveness. The WSJ
discusses Dr.Hu Weimin of Loudi, who offers sensible preventive care
measures and low-cost prescriptions to a burgeoning population of
patients. He has been ostracized and even beaten by doctors and
barred from the wards of Loudi General Hospital because he has cut into
their revenues. “Academic studies show that 50% of all Chinese
health-care spending is for drugs.” Some 63.8% of medical
expenditures in China are paid privately, 87.6% coming out of the
pockets of individuals—higher even than the U.S. “With his Web
site, he manages some 7,000 patients and runs a high-blood-pressure
support group with 50,000 members…” (3/14/07)
199.
Getting Hospitals off Drugs
One of the
impediments to health care reform is that the system incentivizes
doctors and hospitals to spend money on the unnecessary—and does not
reward them for frugality. In “A Novel Plan Helps Hospital Wean
Itself Off Pricey Tests,” Wall Street Journal, January
12, 2007, p. A1, we learn how Virginia Mason Medical Center in Seattle
has taken some halting steps to get off the tests, procedures, drugs
bandwagon. “A novel solution, crafted with the help of the big
employers, ultimately let Virginia Mason share in some of the savings
it created—by paying the medical center more for some cheaper
treatments. It offers a lesson in dealing with one of the most
confounding elements in America’s health-care crisis: a perverse system
of payments that rewards doctors and hospitals not for how well they
treat patients, but for how much they treat them.” “Virginia
Mason's move is a gamble. Only Aetna, which accounts for 10% of
the medical center’s business, has adjusted fees to reward its more
efficient care. Seattle’s two biggest health insurers, Regence
Blue Shield and Premera Blue Cross, haven’t matched the move so far.
Medicare, despite its own experiments, doesn’t have the
flexibility to change its payments for one hospital—and it accounts for
a third of Virginia Mason’s business. Virginia Mason, a
not-for-profit that is satisfied with an annual 1% to 3% operating
margin, still hasn’t replaced all its lost revenue.” “The medical
center has pursued efficiency by adopting some assembly-line methods of
Toyota Motor Corp. and Hitachi Ltd., which hospital officials and
doctors observed on a visit to Japan in 2002. For instance,
Virginia Mason rerouted patient traffic in its cancer center, cutting
the time patients had to wait for chemotherapy from four hours to 90
minutes.” (2/28/07)
198.
Cholesterol and Diet? Maybe
When one does
comparative analyses of heart disease incidence in various nations, one
can often find comparable disease rates in nations with quite disparate
fat intake rates. Namely, there are all sorts of anomalies that
suggest that the simplistic cholesterol studies by which American
doctors set their compass and which drives the vast dispensation and
usage of Lipitor and its statin cousins may not hold water. Also
more data on the danger of statins is coming to light which we will
share in a future entry. While looking harder at the science, we
would still say cut your fats; in fact, cut most everything except
vegetables and fruits. But don’t look askance at others who don’t
share your bias. For an very amusing look at some of the ‘fat’
anomalies, take a peek at the very amusing “The Case of
the Missing Data,” which suggests that our understanding of heart
disease is still pretty primitive, in spite of all the half baked
theories that are foisted upon us. (2/14/07)
197.
Trust for America's Health
The Trust for America’s Health
is trying to put preventive health at the top of our healthcare agenda
and hopes to restore the public health system in the United States.
Its
annual study just said that we are rather unprepared for any major
emergency, be it a pandemic or a terrorist threat. Buried in its
website are rankings of all the states according to a variety of health
yardsticks. In troubled states, one will detect considerable
weakness on child mortality and on other child issues. (1/31/07)
196.
Hibernation for Humans?
Cell biologist
Mark Roth has done research on “induced metabolic hibernation, in which
he has shown that it is possible to reversibly reduce the core
temperature of mice to 10 degrees Celsius without loss of life or
neurological problems,” which, in theory, could lead to breakthroughs
in the treatment of trauma and cancer. See
“Buying Time Through Hibernation on Demand,” Fred Hutchinson Cancer
Research Center Release, April 21, 2005. For an abstract, see
“H2S induces a suspended animation-like state in mice.” It is
thought that such treatment could, for instance, save accident victims
by putting them on ice, as it were, until they can be treated at a
full-scale emergency facility. (1/24/07)
195.
Preventive Health Websites
“Web Site
Tallies Your Risk of Disease and Tells you What You Can Do About
It,” Wall Street Journal, October 31, 2006, p. D1. The site www.yourdiseaserisk.com,
created by the Harvard Center for Cancer Prevention, provides custom,
rather than generic information, to help patients understand their
health situation and the odds that they will get a severe
disease. “More important, it also spits out a tailored action
plan on ways to lower risk for health problems.” “Other Web sites
offer calculators to help users assess their risk for various health
problems.” The American Heart Association offers one at www.americanheart.org, but
it does not take into account enough variables. The National
Cancer Institute’s www.cancer.gov/bcrisktool
suffers from the same sort of problem: it does not take enough
individual variables into account. The Harvard site lets users
calculate their risk for “12 different cancers … heart disease, stroke,
diabetes and osteoporosis.” (12/27/06)
194.
Hyper-Germs and the Power of Soap
We cannot over-emphasize the importance of the rise of
superbugs immune to traditional antibiotics—a topic on everybody’s lips
that is much remarked upon in the media. The New York Times,
for instance, opined that “Concern Mounts as Bacteria Resistant to
Antibiotics Disperse Widely” (August 22, 2006). We have
previously commented on “New Classes of
Antibiotics,” talking about some scientists who are trying
to develop radically different antibiotics that can do battle with a
range of pill-resistant diseases that have sprouted up. Oddly
enough, Big Pharma, puzzled by the difficulty of uncovering effective
new antibiotics, has dropped out of the fight. The infection
problems are accentuated by widespread and unnecessary use of
antibiotics which leads to the development of resistant bacterial
strains but which often kills off beneficial bacteria, especially in
the human gut. Promiscuous use of antibiotics in very young
children is credited with creating higher asthma rates, especially when
used in the first year of an infant’s life. Hospital infections,
especially in America, run rampant: it is such a problem that, by
default, rural populations often live longer simply because they don’t
have access to hospitals where they would otherwise stand a good chance
of getting a life-threatening infection.
Forbes (June 19, 2006, pp.60-74) does
a fine job with the subject in an article entitled “Germ Warfare,”
discussing “six strains of killer bacteria, built for destruction and
rapid reproduction and bred in hospitals nationwide, [that] are among
those that worry doctors most.” They are: Methicillin-resistant
staphylococcus (MRSA), which causes 100,000 hospital infections a year;
Clostridium difficile, which causes 400,000 cases of diarrhea annually;
Klebsiella pneumoniae, of which cases are up almost 50% in five years
and, when untreated, kills two-thirds of patients; Acinetobacter
baumannii, which is soil borne and heavily afflicts soldiers in Iraq
and Afghanistan; Vancomycin-resistant Enterococcus Faecium (VRE), which
is hard on those with weak immune systems and accounts for 10% of
hospital infections; and Pseudomonas aeruginosa, which accounts for 18%
of hospital-acquired pneumonia.
“100,000 Americans die of hospital -bred
infections” each year; “2 million patients get hospital
infections…. This crisis costs $30 billion a year.”
Sundry smaller companies are doing the
pathfinding work now on new antibiotics and other drugs. Stuart
Levy, a Tufts infectious disease expert, co-founded Paratek
Pharmaceuticals, which is testing a souped-up tetracycline. He is
author of The
Antibiotic Paradox, which deals with the over-use of
antibiotics and the subsequent outbreak of antibiotic-thwarting killer
bugs. Roy Vagelos, retired chairman of Merck, now heads
Theravance, which crushes fragments of old drugs to make powerful new
versions. He is aiming for a new and improved vancomycin.
Old-fashioned treatments, such as silver,
have shown considerable ability to reduce infections, as we mentioned
in “Silver
Standard.” As well strict observance of protocols in
intensive care units, with discipline reinforced at the highest level
of a hospital, can result in a “95%
Success Rate” in reducing infections.
The more things change, the more things stay
the same: cleanliness is still next to godliness. Simple
hand-washing and other old-fashioned hygienic measures among hospital
personnel, and particularly doctors, can cut hospital infections
dramatically. “Strict infection-control measures and prudent
antibiotic use have let hospitals in the Netherlands avoid the
resistant staph strains that plague most U.S. hospitals.
Hospitals test patients to identify carriers of staph, which
‘colonizes’ the nose when it is not causing infection. In the
Netherlands at-risk patients go into isolation, and doctors who are
carriers are sent home and can’t return until they are cleared, says
Margaret Vos, who heads infection control at Erasmus University Medical
Center.” Testing has reduced infections 90% at the University of
Pittsburgh Medical Center, and other tests are at various stages.
Prophylactic measures that prevent infection are more effective, and
more cost efficient, than drugs administered after the fact.
But we cannot under estimate the difficulty
of getting professional health personnel to take hygiene
seriously. Doctors are the worst of the bunch. Not to be
missed in this respect is “Selling Soap,” New York Times Magazine,
September 24, 2006, pp. 22-23. “In its 2000 report ‘To Err Is
Human,’ the
Institute of Medicine estimated that anywhere from 44,000 to 98,000
Americans die each year because of hospital errors—more deaths than
from either motor-vehicle crashes or breast cancer—and that one of the
leading errors was the spread of bacterial infections.”
Cedars-Sinai in Los Angeles “needed to
devise some kind of incentive scheme that would increase compliance
without alienating its doctors. In the beginning, the
administrators gently cajoled the doctors with e-mail, faxes and
posters. But none of that seemed to work. (The hospital had
enlisted a crew of nurses to surreptitiously report on the staff’s
hand-washing.) ‘Then we started a campaign that really took the
word to the physicians where they live, which is on the wards,’ Silka
recalls. ‘And, most importantly, in the physicians’ parking lot,
which in L.A. is a big deal.’”
“When
the nurse spies reported back the latest data, it was clear that the
hospital’s efforts were working—but not nearly enough. Compliance
had risen to about 80 percent from 65 percent, but the Joint Commission
required 90 percent compliance.” “They pressed their palms into
the plates, and Murthy sent them to the lab to be cultured and
photographed. The resulting images, Silka says, ‘were disgusting
and striking, with gobs of colonies of bacteria.’ The
administration then decided to harness the power of such disgusting
images. One photograph was made into a screen saver that haunted
every computer in Cedars-Sinai. Whatever reasons the doctors may
have had for not complying in the past, they vanished in the face of
such vivid evidence.” (11/15/06)
Update: Pre-Screening and Discipline
Handwashing can do a lot. But more complex strategies seem to be
indicated in countries where super-infections are well
entrenched. Apparently scorched-earth policies in the Netherlands
and Scandanavia have kept in-hospital infections rates low. In
England, University of Bath researcher Mark Enright notes, the rates are
higher. Something different is required where microorganisms have
gotten well entrenched inside hospitals.
All that said, prescreening
of patients can make a big difference. “One strategy, long
popular in some Northern European countries and gaining traction here,
is to screen every patient admitted to the hospital, and isolate those
who are infected. This morning’s New York Times describes
a Pittsburgh VA Hospital that’s adopted mandatory testing of patients
and some simple measures to cut the number of MRSA infections from
about 60 per year to 17 last year.” (11/7/07)
Update:
Positive Deviance
Working with hospitals around the country on MRSA, “the Sternins take
an unorthodox approach…known as positive deviance, or P.D., which
builds on …their health work in poor countries in Southeast
Asia.” Some are not suffering from the MRSA problem.
“Understanding precisely what the 30 percent are doing differently, and
then encouraging these positive deviants to educate the other 70
percent, can effect significant changes in group behavior.” The
MRSA rate at a Pittsburgh hospital dropped 50 percent after adopting
cleaning checklists and other notions suggested by everybody ranging
from doctors to janitors. An orderly at another hospital came up
with a good method of removing infected hospital gowns: his name
was Jason Palmer and this tactic is called the Palmer Method. See
more at www.positivedeviance.org
New York Times Magazine,
December 14, 2008, p.68. Jerry Sternin is working on this
initiative at Tufts University. The idea here is to what a what a
minority—sometimes a very small minority-is doing right, and using this
is a model for the whole group. Ibsen, we think, called this the
compact minority. (1/6/09)
193.
Competitive Disadvantage
In “Risk Pool,” New Yorker, August 8, 2006,
Malcolm Gladwell discovers that the dividing line between the Asian
Tigers (i.e, the high growth economies and companies of Asia) and the
American and European sluggards is dependency costs. In other
words, Westerners, and particularly Americans, are laying out huge
expenditures on a company by company basis for pensioners both for
health and retirement. Too high a dependency burden puts an
unsupportable overhead cost burden on all companies, particularly those
with overcapacity—such as the car companies:
The difference is that in most countries
the government, or large groups of companies, provides pensions and
health insurance. The United States, by contrast, has over the
past fifty years followed the lead of Charlie Wilson and the bosses of
Toledo and made individual companies responsible for the care of their
retirees. It is this fact, as much as any other, that explains
the current crisis. In 1950, Charlie Wilson was wrong, and Walter
Reuther was right.
Charlie Wilson was Engine Charlie Wilson, of
course, the famed leader of GM who railed against pooled pension
schemes, preferring to things on a company by company basis.
Walter Reuther was the auto union leader who understood that both
workers, companies, and the countries would enjoy more stable growth if
the burden was spread over a range of companies.
“Demographers
estimate that declines in dependency ratios are responsible for about a
third of the East Asian economic miracle of the postwar era; this is a
part of the world that, in the course of twenty-five years, saw its
dependency ratio decline thirty-five per cent. Dependency ratios
may also help answer the much-debated question of whether India or
China has a brighter economic future. Right now, China is in the
midst of what Joseph Chamie, the former director of the United Nations’
population division, calls the ‘sweet spot.’ In the
nineteen-sixties, China brought down its birth rate dramatically; those
children are now grown up and in the workforce, and there is no
similarly sized class of dependents behind them. India, on the
other hand, reduced its birth rate much more slowly and has yet to hit
the sweet spot. Its best years are ahead.” (11/1/06)
192.
Chilies
Fight Cancer
“Capsaicin, the chemical that makes chile peppers hot, may have the
power to destroy cancer cells” (The Week, April 7, 2006, p. 20).
Cedar-Sinai in California has discovered that it shrinks prostate
tumors in mice 80%, and, in lab tests, the spice killed 75 percent of
human cancer cells. See “Capsaicin, a component of red peppers,
inhibits the growth of androgen-independent, p. 53 mutant prostate
cancer cells.” See
PubMed. (10/11/06)
191. Microbial Fat
“It’s clear that diet and genes contribute to how fat you are.
But a new wave of scientific research suggests that for some people,
there might be a third factor—microorganisms” (“Fat Factors,” New
York Times Magazine, August 13, 2006, pp. 28-33, 52-57). “One
year ago, the idea that microbes might cause obesity gained a foothold
when the Pennington Biomedical Research Center in Louisiana created the
nation’s first department of viruses and obesithy … headed by Nikhil
Dhurandhar.” Jeffrey Gordon at Washington University in St. Louis
believes obesity is related to intestinal microorganisms.
(10/4/06)
190.
Cleanliness and Antibiotics Equal Allergies
A Duke study
tentatively confirms that the too-hygenic environment children
encounter in advanced developed countries plays a significant part in
the development of allergies. The study suggests that an overly
hygienic environment could simultaneously increase the tendency to have
allergic reactions and the tendency to acquire autoimmune disease,
despite the fact that these two reactions represent two different types
of immune responses. See
“Increased IL-4 production and attenuated proliferative and
pro-inflammatory responses of splenocytes from wild-caught rats (Rattus
norvegicus),” Scandanavian Journal of Immunology and other
articles. Meanwhile, British Columbia
researchers believe that asthma rates among children continue to
rise because of excessive use of antibiotics. Infants who intake
antibiotics during their first year of life are twice as likely as
other children to develop asthma. Earlier studies within the
United States have led to much the same conclusion. (9/27/06)
189.
The Genes Will Out
For the first
time, really, gene therapy seems to be getting at tumors. See the
Wall Street Journal, September 1, 2006, pp. All &
A13. Such therapy had only worked in a very small cohort—2 out of
17 patients with advanced melanoma. Genes had previously worked
for other kinds of disease conditions, but this is the first time they
have bitten into cancer. The work was done by Dr. Steven
Rosenberg of the National Cancer Institute. He took T-Cells and a
receptor from one patient, and a couple of patients then showed
“dramatic and durable regression in their tumors.” They’re still
clear a year and one half later, and none of the patients are showing
side effects from the treatment. Rosenberg and others wondered
why the treatment did not work in more patients, speculating that a
weak receptor or other technical difficulties could have limited the
results. See the
National Cancer Institute. (9/20/06)
188.
Heart Tricks While You’re Waiting
A string of recent technological developments in
Japan are holding out hope for patients awaiting heart transplants,
particularly children. The goal of the researchers involved in
these developments is to improve ventricular assist devices (VADs) by
making them smaller and more functional, so that they can be implanted
into young children and others with serious heart problems. VADs
help the heart to pump blood around the body. For patients awaiting
transplants, they play a critical role, helping them to survive until
transplant surgery can be performed.
VADs
come in two basic designs, with the pump outside the patient’s body or
implanted inside the body. Current models are large, which
restricts their range of use. Patients must be confined to their
beds while using them, and the VADs’ large size prevents them from
being used on children and others with small bodies.
But all that may change in the years ahead,
thanks to the development of a prototype of the world’s smallest
general-use VAD. The breakthrough is the result of joint research
between Tokyo Medical and Dental University and the Tokyo Institute of
Technology.
The device’s pump, a critical component, is
circular in shape and small enough to fit into the palm of an adult’s
hand. It measures a mere 6.5 centimeters in diameter and is just
3.25 cm thick. Due to its small size, researchers believe there
is a high likelihood that the new VAD can be used in children as young
as 5 years of age for short periods of time. Clinical testing on
the new generation of VAD is planned for around 2009.
The
device is implanted into the body of a patient whose heart is extremely
weak from illness. It is then connected to their heart and sends
blood around the body through the turning of the pump’s impellers.
The researchers working on the project hope one day to develop a
device that can operate even when the user goes outdoors.
Another recently developed VAD is the
result of joint research in Japan by Sun Medical Technology Research
Corp. and several universities. This device is already in use in
one patient. The patient had it implanted in an operation in May
2005 and was released from the hospital the following February, after
recovering to the point of being able to stand up and move around.
The developers hope to have this VAD in widespread use in a few
years’ time.
Terumo Corp., Japan, a major medical
equipment maker, has completed clinical trials of its own VAD, expected
to be sold in Europe by the end of fiscal 2006 (April 2006 to March
2007).
Such
promising developments are good news for transplant patients, many of
whom spend prolonged periods waiting for their operations. This
makes the VADs’ role of supporting hearts all the more critical.
(From Trends in Japan.) (8/30/06)
187.
Online Brokers for Lab Tests
A host of firms
including MedLabUSA.com, MyMedLab.com, HealthCheckUSA, DirectLabs.com,
etc. are acting as brokers over the Internet to directly secure
consumers lab tests prescribed by doctors or simply desired by the
consumer. They have tie-ins with local labs in the area of each
customer. The savings can add up to 75% or more. Quest
Diagnostics and Laboratory Corp of America Holdings, the biggies in the
lab game, have held back from this market, since they are so tied in to
physicians and hospitals. It is anticipated that this market will
grow as consumers control more and more of their outlays in the
future. See the Wall Street Journal, June 20, 2006, p.
D4. (8/2/06)
186.
Checking out Prescriptions and Treatments
Consumer
Reports long has
provided an online database on prescription drugs as part of a
partnership with the American Society of Health-System
Pharmacists. Now it has added in for a $9 annual fee herbs and
natural medicines from the Natural Medicines Comprehensive database of
the Therapeutic Research Center in Stockton, California, as well as its
guide to medical treatments. Conceptually this is a terribly good
idea, but we must add that the quality of these databases varies
immensely, and we cannot avow that CR has tied itself to the
right partners. (7/5/06)
185. Anthrax Killers
Not all biological weapons are created equal. They
are separated into categories A through C, category A biological agents
being the scariest: they are easy to spread, kill effectively and
call for special actions by the pubic health system. One of these
worrisome organisms is anthrax, which has already received its fair
share of media attention. But work in Vince Fischetti’s
laboratory at Rockefeller University suggests that a newly discovered
protein could be used to fight anthrax infections and even
decontaminate areas in which anthrax spores have been released.
“Anthrax is the most efficient biowarfare agent. Its
spores are stable and easy to produce, and once someone inhales them,
there is only a 48-hour window when antibiotics can be used,” says
Fischetti. “We’ve found a new protein that could both potentially
expand that treatment window and be used as a large-scale decontaminant
of anthrax spores.” Because anthrax spores are resistant to most
of the chemicals that emergency workers rely on to sterilize
contaminated areas, a solution based on the protein would be a powerful
tool for cleaning up after an anthrax attack.
All bacteria, anthrax included, have natural
predators called bacteriophage. Just as viruses infect people,
bacteriophage infect bacteria, reproduce, and then kill their host cell
by bursting out to find their next target. The bacteriophage use
special proteins, called lysins, to bore holes in the bacteria, causing
them to literally explode. Fischetti and colleagues identified
one of these lysins, called PlyG, in 2004, and showed that it could be
used to help treat animals and humans infected by anthrax. Now,
they have identified a second lysin, which they have named PlyPH, with
special properties that make it not only a good therapeutic agent, but
also useful for large-scale decontamination of areas like buildings and
military equipment (News Release, Rockefeller University, April 21,
2006).
Fischetti
hopes to combine PlyPH with a non-toxic aqueous substance developed by
a group in California that will germinate any anthrax spores it comes
in contact with. As the spores germinate, the PlyPH protein will
kill them, usually in a matter of minutes. The combined solution
could be used in buildings, on transportation equipment, on clothing,
even on skin, providing a safe, easy way to fight the spread of anthrax
in the event of a mass release. See the Journal of
Bacteriology 188(7): 2711-2714 (April 2006). (6/28/06)
184.
Cholesterol Two
The first act in the drugmakers march against cholesterol
was a whole line of statin-class drugs, today led by Pfizer’s Lipitor,
which that company snapped up through an unfriendly acquisition of
Warner-Lambert. Lipitor is now ladled out at the rate of $11
billion a year, the heart doctors blind to the possible side effects of
the statin drugs. Cholesterol has been viewed as the prime
culprit in heart disease since the vaunted Framingham study, and one
only meets an occasional physician who looks at heart disease in a more
complex way.
Now
we’re talking about “A Second Bullet for Cholesterol,” Business Week,
December 5, 2005, pp.77-78. What’s up is the addition of pills to
raise HDL, or good cholesterol. Sundry products are either now
being sold or about to be marketed, such as Niaspan from Kos
Pharmaceuticals (with about $400 million in sales), Acomplia from
Sanofi-Aventis, a weight loss drug with HDL cholesterol possibilities,
Torcetrapib from Pfizer which is mixed with Lipitor to provided a
one-two punch cocktail, and Avant’s vaccine. (6/7/06)
183. Close at Hand
The fine medical writer and physician Jerome Groopman
raises more than one interesting question in “Being There,” The New
Yorker, April 3, 2006, pp. 34-39:
In 2003,
emergency rooms in the United States treated nearly a hundred and
fourteen million people; about one in every hundred received CPR or
underwent another kind of resuscitation procedure. Resuscitations
are gruesome … and just fifteen percent, at most, are successful.
It’s a surprise to many that the revival
rate is so low, but it only emphasizes that CPR and other procedures
are best begun well before a patient can reach a hospital. In
“Distributed Defibrillators,” we underline the great success Las
Vegas has had, simply by putting defibrillators in casinos for quick
and easy access.
Groopman
goes on to talk about a movement in medicine to close family relatives
into the emergency room to witness such crisis procedures. While
this practice is still not widespread, Groopman expects it to grow,
since openness plus patient and family involvement are becoming more
and more characteristic of modern medicine. (5/31/06)
182. Chiles and
Cancer
A research team
at Cedars-Sinai Medical Center in California, in conjunction with UCLA,
has found that capsaicin (one of chile’s firey ingredients) shrinks
tumors some 75% in mice with prostate cancer. Phillip Koefler,
the study’s senior author, notes, in effect, that the capsaicin abets
“cell death,” a process cancer cells seek to avoid. Additionally
it tends inhibit cancer cell growth. See
Cedars-Sinai Release, March 15, 2006. See also
“Cancer Research.” And for anti-microbial aspects of spices,
see “Spice
and Life.” (5/24/06
181. Smelling
out Malaria
The female mosquito, carrier of malaria, “locates her
human prey with her exquisite sense of smell. She can discern
human scent from 50 meters away.” Laurence J. Zwiebel of
Vanderbilt, John Carlson of Yale, and three other research groups in
Europe and Africa have joined together to see if these blood-sucking
killers can be brought low by their noses. They are developing
odor blends to lure mosquitoes into traps. See “Serial Killer,” Yale
Alumni Magazine, March-April 2006, pp.53-58. In 1986, Carlson
“established what was probably the only fruit fly olfaction lab in the
country and only the third he knows in the world.” Twenty years
later, there are more than 50. Attending a London conference on
mosquito olfaction in 1995, he learned that “10 percent of the world’s
population gets” malaria every year.
Carlson
has used fruit flies as proxies for mosquitoes in his lab experiments.
“Carlson’s daunting task was to identify the genes governing
insect olfaction.” It took him and colleagues until 1999 to
identify “the first odor receptor genes in the fruit fly.” The
thought is that repellants and attractants and other devices can be
developed that play on the olfactory genes of the mosquitoes.
(5/17/06)
180. Metals
Again
More and more,
we are discovering the part that metals and sundry minerals play in
inhibiting illness, and—in some instances—in provoking it. We
have discussed both arsenic and silver elsewhere. Brian DeDecker,
a cell biologist at Harvard Medical School, just has written abut the
role of gold and platinum in Nature Chemical Biology.
“Noble Metals Strip Peptides from Class II MHC Proteins,”
disabling the auto-immune system and possibly providing relief for
lupus, child diabetes, and rheumatoid arthritis. See The
Economist, March 6, 2006, p. 74. “Dr. Dedecker and his team
have screened some 30,000 chemical compounds … that might adversely
affect the proteins in question … without much success.” Just
recently they tried out drugs approved for other purposes: “two …
worked, and they had a surprising element in common: platinum.”
In general, not just platinum, but the whole class of noble metals
(such as palladium and gold) worked well. Some gold-based drugs
had long worked slowly against arthritis. Now that it is
understood that they curb MHC Protein, it is thought that faster acting
drugs can be devised. (4/19/06)
179.
Distributed Defibrillators
“Las Vegas casino security officers
have restored the heartbeats of about 1,800 gamblers and employees in
the past nine years, according to the Clark County Fire
Department.” See the Wall Street Journal, January 28-29,
2006, pp. Al & A10. Bryan Hindsoe, a George Washington
University emergency-medicine doctor and co-author of paramedic
textbooks, alleges that it’s now safer to suffer cardiac arrest in a
casino than at a hospital.
“Casino security officers have become so
adept” with defibrillators “that they usually decline offers of aid
from physician bystanders.” Authoritative bodies such as the
American Heart Association are now calling for wide distribution of the
devices and broader use by lay persons.
Richard Hardman, a paramedic in the Fire
Department, pushed the idea of casino personnel having and operating
defibrillators for the stricken. He got Stan Smith, vice
president of risk management at Boyd Gaming (Stardust Casino) to
cooperate.
“The state’s ‘good Samaritan law,’ giving
legal protection to bystanders who help in a medical emergency, was
extended to explicitly cover users of defibrillators, after lobbying by
casinos and Mr. Hardman.”
“The study’s survival rate astonished
specialists in emergency medicine. ‘This was groundbreaking—it
showed what can be accomplished with quick response,’ say Leonard Cobb,
professor emeritus of medicine at the University of Washington and the
father of Seattle’s paramedic program, widely hailed at the fastest-
reacting big-city operation in the country.” Now corporations,
such as Proctor & Gamble, and other institutions are laying in the
defibrillators which keep falling in price.
We
would further suggest that lay people should be both allowed and
trained to implement a number of doable medical practices which can
conceivably lead to broader, faster implementation of sound medical
practices at an affordable cost. We ourselves have seen that
experienced nursing personnel in hospitals and elsewhere can often both
suggest and render sensible medical procedures that would not occur to
physicians of rather narrow experience. (3/22/06)
178. Bird Flu
Bird Flu is on the fly, and it is
becoming a real worry. A case here and a case there is cropping
up—particularly in bird populations, brought on by wild birds on the
wing.
Scientists of merit are taking its moves
quite seriously, and are worried about a global pandemic. This
rise in concern, from a yellow to a red level if you will, has been
brought to our attention by Max Wallace, a healthcare and biotech
entrepreneur in the Research Triangle. We intend to give it a lot
of attention—right here.
The implications are many. It’s not
only a threat to people across the globe, but it already is having
business and economic implications. Some businesses are already
beginning their crisis planning, trying to imagine how they can carry
on with decimated labor forces. “Avian-Flu Concerns Overseas” are
dampening U.S. chicken exports, according to the Wall Street Journal,
March 11-12, 2006, p. A5. Several importers, especially in
Europe, are consuming less chicken, even though proper killing knocks
out the virus. “According to the World Health Organization, the
H5N1 virus has killed 97 people since 2003 in the developing world,
where people … live in much closer contact with poultry than they do in
the West.” “The wholesale price of so-called dark meat has
plunged to about 14 cents a pound in recent weeks, compared with about
41 cents a pound last summer.” Brazil plans to cut production
about 15%, but currently the U.S. production schedules calls for a
marginal increase.
Mainland China, which already has rather
serious, unmet healthcare problems, is once again a source for this
latest flu, and some feel it is under-reporting its flu cases.
One wonders whether world public health bodies can do enough back
channel communication with China to begin to get at some of the sources
of its ongoing virus problems—or whether officialdom will try to
stonewall this growing problem.
There are outbreaks everywhere. See
“Sinister Droppings,” The Economist, February 18, 2006, p.
51. Italy, Greece, Austria, Germany. Official assurances
notwithstanding, chicken consumption has dropped 70%. Nigeria, a
heavy poultry country, has had an outbreak, though there are few signs
so far elsewhere in Africa. Both Azerbaijan and Iraq are
worrisome spots.
Controlling bird flu is a complex problem
and raises some of the very same issues that we encounter with other
kinds of viruses—computer outbreaks, terrorism, etc. It requires
intense collaboration that is not altogether easy, since the world’s
public health system is rather broken. Clearly there is fertile
ground here for the application of network theory—a growing body of
knowledge not well understood by governments anywhere.
It is perfectly clear that national
jealousies and scientific ambitions are an impediment to dealing with
the disease. Increasingly we are discovering that the only means
of rapidly dealing with emerging threats is efficient knowledge
markets. That means widely distributed nodes (researchers) bound
together by an open network as well as the will to work together.
“WHO
… runs a database limited to a select group of scientists and
containing a massive trove of data—some 2,000 genetic sequences of the
virus, around a third of the world’s known sequences.” See the Wall
Street Journal, March 13, 2006, pp. B1-B2. Ilaria Capua an
Italian veterinarian working on avian influenza just received a sample
of virus from outbreak in Nigeria. Instead of supplying her
genetic data to the secretive WHO cache, she posted her findings on the
Internet in a public database. WHO, perhaps justifiably, says the
closed database is a compromise necessary to get some governments to
share the data: scientists agree not to publish results based on the
data without prior consultation. Officials and scientists from
the U.S., Switzerland, Croatia, Slovenia, United Kingdom, Iran, and
Niger have backed her stand, and often have given her permission to
make public sequences they have supplied. Her data is stored at
GenBank, run by the National Center for Biotechnology, part of the
National Institutes of Health. (3/15/06)
Update: Tracking
Avian Flu.
Airports. “The nation’s major airports aren’t prepared to quarantine a
planeload of international passengers, if someone is suspected of
carrying bird flu…” (USA Today, March 10, 2006, p.2A).
Honolulu is better prepared than airports on the mainland to spot and
handle flu suspects. The CDC is watching Hawaii to gain insight
as to how to control ports and airports in general.
Quantity Not Quality. More generally,
everyone involved with avian flu is having a hard time tracking
it—including the science, public health controls, outbreaks, dispersal
of the virus, etc. There are a host of sites—from WHO to national
authorities to self-invented experts: our team has not been able to
work its way through all of them. But we find that many have an
axe to grind, from furthering national or scientific jealousies, to
expanding on particular political biases. The UN is trying to do
a good job, but as might be expected with this and other institutions,
it falls behind the information curve, as events race ahead of its
statistics. We have yet to find a group that is doing a comprehensive
job of covering avian events, much less a site where the information is
presented in an accessible form.
The media is clear that it should be
watching, but does not know how to do it. The New York Times’s
Science Times (March 28, 2006, pp. D1-D8) devoted a special section to
the topic. It calls Avian Flu “The Uncertain Threat.” The
title article, which is in itself indecisive and wandering, is entitled
“How Serious Is the Risk?” Dr. David Nabarro at the UN is a
worrier; Dr. Jeremy Farrar at the Hospital for Tropical Diseases in Ho
Chi Minh City, thinks a human pandemic is unlikely, having watched the
slow progress of the disease over some 3 years.
Roeder. In the absence of an
authoritative and decisive news source, we suggest that researchers
track what we will call here science entrepreneurs who are trying to
manage, understand, and perhaps offer solutions to the disease.
In general the Wall Street Journal has been better at turning
up these people than other publications. See, for instance,
“After Fighting a Cattle Disease, Vet Turns to Birds,” Wall Street
Journal, March 16, 2006, which focuses on Dr. Peter Roeder, “a
60-year-old British veterinarian … who has spent decades fighting”
rinderpest in Africa and Asia, a devastating disease that has long
decimated cattle herds. “Dr. Roeder … has recently been in
Indonesia, helping lead the charge against another—the avian influenza
know as H5N1, or bird flu.” Roder knows that “mass vaccinations
don’t always work as well as narrowly targeted attacks on the
disease.” “The key to rinderpest’s defeat, he says, lay in being
selective.” Bird-flu experts are beginning to flock to his
thinking: at first they had been thinking about vaccinating
billions. Now they are talking about focusing on Guangdong
province which is a particularly feisty breeding ground. At a
macro level, Roder also makes a lot of sense: the general problem in
health is to learn how to leverage scarce resources for maximum effect,
so much of healthcare being stridently wasteful.
Niman. Dr. Henry L. Niman enjoys a
mixed reception in the scientific community, but, nonetheless, he has
been a successful communicator about bird flu, leading a voluntary band
of bloggists, who collect and spread information about. See “A
Bird Flu Watched Developes a Following Through the Internet,” Wall
Street Journal, March 24, 2006, pp. B1 and B4. In his
Pittsburgh home, “the 57-year-old biochemist keeps vigil over a blog
and explosion of offshoot internet discussion groups tracking the avian
flu virus….” “They believe mainstream scientists are missing
important clues about the virus’s evolution…” He now has his own
business called Recombinomics where he hopes to develop vaccines.
In general mainstream researches are skeptical about his research and
flu theories. He does think that we have moved decidedly closer
to a flu pandemic, obviously scaring his tribe of adherents.
Oddly, the WSJ did not appear to publish a link to his website.
It is helpful to peek at
WSJ’s Avian Flu Tracker, which is anecdotal but gives you a decent
sense of the evolving news.
George Mason. Curiously enough, not
many comment on the avian flu site that has been hatched by Tyler Cowen and Silviu
Dochia at George Mason University. The Masonites are doing more
than basketball.
“Avian Flu—What we need
to know.” It’s literate and wanders to some topics we do not
see elsewhere. Mr. Cowen has even authored a paper on the
subject: “Avian Flu: What Should be Done,” November 2005, which
is hardly definitive, but is creative and worth quite a look (Read the
full article, not the summary.)
Mr. Cowen and Mr. Dochia are economists, and we are yet to determine
how their avian flu chronicle connects up with their specific economic
interests, which we may learn about when we read Mr. Cowen’s other blog
“The Marginal Revolution,”
which is on economics and the efforts at the margin that can improve
economies. We are pleased, incidentally, to see that George Mason
has a flu information
page available for students that touches on the rudiments of flu
and avian flu. It is not very good, but at least it exists.
(4/5/06)
Update: Indonesia
Worsening
Indonesia
is soon to overtake Vietnam as the site of worst human outbreaks of
Avian flu. Forty-two people have died over the last year (New York
Times, July 21, 2006, p. A10). Thailand got control of the
flu by killing millions of chickens and by Vietnam instituted mandatory
vaccinations. Indonesia has tried limited vaccinations and flock
culling with limited success. (8/9/06)
Update: Bird Flu Vaccine
GlaxoSmithKline reports that it now has produced effective
human bird-flu vaccine (Wall Street Journal, July 27, 2006,
p.A2). “In a clinical trial of 400 people, two doses of Glaxo’s
vaccine produced a strong immune response against the H5N1 virus in
more than 80% of the people who received it.” These results are
much better than those achieved with vaccines of other drug
companies.
Meanwhile,
slowly but surely, the bird flu threat continues to intensify
(“Thailand Alert for Bird Flue Is Expanded,” New York Times,
August 6, 2006, p. 6). Officials have “put eight more provinces,
including the Bangkok area, on a bird flu watch list.” “The
outbreaks in Thailand and neighboring Laos, where bird flu was found on
a farm last month, renewed fears that the disease is flaring up again
in Asia.” “Indonesia and Vietnam have each had 42 deaths, the
highest number of confirmed human deaths anywhere in the world.”
(8/23/06)
Update: Microchip Flu Test
“Scientists have developed a microchip-based test that could allow more
laboratories to quickly diagnose and pinpoint the origin of flu
viruses, including the H5N1 avian-flu strain” (Wall Street Journal,
August 29, 2006, p. D4). The FluChip represents a research
collaboration between the Centers for Disease Control and the
University of Colorado at Boulder. It will ostensibly be two
years before “the test is commercialized” and becomes inexpensive
enough for wide laboratory use. Results were included in the
August 2006 issue of the
Journal of Clinical Microbiology. (11/29/06)
177. Arsenic
for Brain Cancer
We keep traveling around in circles. Silver, an old cure for
pesky infections, is now being revived to stave off hospital
infections. Once upon a time, arsenic (in the form of salvarsan)
was the only cure for syphilis. Now it’s the hope for some
intractable brain cancers. (2/22/06)
176. Silver Standard
We have always preferred silver to gold—now we can
rationalize our aesthetic choice. Silver, it turns out, has
curative powers. Its use against bacteria dates back to the
ancients. “In 1884, a German doctor named C.S.F. Crede
demonstrated that putting a few drops of silver nitrate into the eyes
of babies born to women with venereal disease virtually eliminated the
high rates of blindness amongst such infants” (New York Times,
December 20, 2005, p. D5). Silver is staging a comeback, because
of bacterial resistance to many antibiotics and because scientists,
manipulating silver ions, can put together more powerful potions.
One
critical application is to deal with runaway hospital infections.
There “bacterial infections” affect 2 million a year, killing some
90,000 patients. It is the worst problem in the hospital
environment, more fatal even than mistakes made in treatments and the
like. “The latest advance for silver therapy comes from AcryMed … that has invented a
process to deposit silver particles averaging 10 nanometers … on
medical devices” Its first customer, I-Flow, makes a silver-coasted
catheter….” (1/25/06)
175. Just Medical Blogs
Thomas P. Stossel, American Cancer Society Professor at
Harvard Business School, has correctly urged us to take medical
journals with a grain of salt. In “Mere Magazines,” Wall
Street Journal, December 30, 2005, p. A16, he finds that they are
regarded with too much reverence, in that the research they include (a)
is not subject to the rigorous detailed examination processes that are
required, for instance, in FDA reviews and (b) is normally
herd-driven—the articles that get accepted tend to tow the party line,
tracking current conventional theories in the medical field.
“Anonymous peer review by jealous competitors has its merits, but it
has a tendency to select for fashionable if relatively unoriginal and
inoffensive papers.” For this reason we should not get so
exercised when editors at the journals raise a storm about researcher
ties to corporate sponsors. Plenty of bad research creeps in with
the good under present editorial guidelines, and there is no clear
indication that corporate sponsorship of researchers, in whatever form,
has created tainted research we should suspect.
However,
and Stossel does not get into this, articles in these journals are now
much, much reported on in the everyday press, even though the research
and results only add up to very tentative hypotheses. Journalists
and readers should be cautioned to take all this research with many
grains of salt. We are all too easily seduced by press reports on
journal articles: research has a way of flipflopping every few
years. (1/18/06)
174. 95%
Success Rate
One really has to perk up when you come across a 95% success
rate. It’s a dirty secret of hospitaldom that infections run
rampant in our best institutions and there’s a good chance you will die
from them rather than from a high-risk operation on your next visit to
the operating room. But John Hopkins has found a way around this,
as we learn from Peter Kindlmann of Yale and Lee Schulman, president of
the Carnegie Foundation for the Advancement of Teaching:
This makes
thought-provoking reading. It is about quality control in
teaching, overtly here in a hospital setting, but by implication also
in an engineering program or a company. It proposes an aggressive
attitude, such as in the Johns Hopkins program (described below) which
is an aggressive drive to lower to zero the infection rate in intensive
care units. The protocols are stringent and are working.
Early on in this
new routine, every nurse was handed two phone numbers—the home phones
of the medical school dean and the university president—and told that
if a physician didn’t follow protocol and refused to abort the
procedure, they were to phone one of these numbers, even at 3 a.m.
That only happened once. The infection rate at Johns
Hopkins for that procedure is now approaching zero.
The piece concludes by asking how much
engineering education and student success in courses could be improved
by similar methods.
Faculty and
teaching institutions face many impediments, just like physicians; the
conditions and capabilities of our students are often unknown. But what
if at some universities the president was called every time a student
failed? This proposal sounds crazy, I know, but that’s just the
point. We’re too comfortable with our failures; we take them for
granted. The good news is that we can do much better. We know a great
deal today about how to organize our institutions and classrooms so
that students not only stay but achieve at high levels, and research in
the cognitive sciences and other fields provides grist for further
improvements. I know we lack the resources. I know we lack
the administrative and policy support. I know that some students
we inherit are already deeply wounded. Nevertheless, we need to
ask much more of ourselves. Education is no place for modest ambitions.
Kindlmann
is abstracting the quotes from Lee Schulman’s “Immodest Proposal” which
can be found on the
Carnegie website. (12/28/05)
173. Strokes—Before
and After
A Simple Test. If you think a friend has had a stroke,
give him or her this simple test: Ask him to smile; ask him to
raise both arms; ask him to speak a simple sentence. If he can’t
do one of the three, call 911 for emergency help. For more on the
success of this procedure, look at the American Heart Association’s
“Just a Minute.” Or, if you prefer, look up the more
complicated
list of warning signs on the American Stroke Association website,
which is a division of AHA.
Life
after Stroke. Again, the American Stroke Association provides
some boilerplate hope on how to deal with life once you have had a
stroke. But, in our opinion, you are best served to look at the
sites of thinking patients who have been through the whole
experience. You will find that the sites put up by patients and
their families vary widely in quality, but will often find the
practical hints that there that answer your particular needs.
Example’s are Joe and Jackie’s
and Stroke Survivors International.
The Stroke Information
Directory provides links to a number of survivor groups.
(12/21/05)
172. Blood
Readers
“Researchers
at Royal Philips Electronics are developing pinprick blood sensors that
can detect certain diseases within minutes. Today’s blood screens
can’t spot malaria at an early stage, when the infection is still
treatable, because the tests don’t pick up trace particles of the
malaria parasite.” The Philips tests can, and the thought is that
it would have high relevance to early detection of heart
problems. It is trying to bring this approach to market as early
as 2009. See Business Week, October 24, 2005. Even
more exciting, we think, is the prospect of biometric sensing systems
which would not even prick the skin to read the blood. The
speculation is that they, too, could do very sensitive readings.
(12/7/05)
171. Surgery and Cancer
Years ago, when
we could offer cancer patients little hope in many instances, we
noticed that surgery seemed to exacerbate an existing cancer and hasten
the death of patients upon whom operations had been performed.
Recent studies suggest that “removing a tumor can trigger a process
that leads to new growth” (Wall Street Journal, September 13,
2005, pp. D1 and D3). “In a database of 1,173 breast-cancer
patients treated with surgery from 1964-1980 … 520 relapsed.” “In
a 2002 paper published in the journal Lancet, colon-cancer patients who
had traditional surgery had a significantly higher rate of relapse than
patients who had a minimally invasive laparoscopic procedure.”
See
http://breast-cancer-research.com/content/6/4/R372.
170. Teeth without Pain
“Swedish
dental implant maker Nobel Biocare … received Food and Drug
Administration approval last May for Teeth in an Hour, a quick,
minimally invasive procedure for replacing several to all of a
patient’s teeth.” Using Nobel software, dentists do a CT scan of
patient’s mouth to perform an analysis. “Nobel’s Swiss factory
uses these plans to make a stencil-like mouthpiece, predrilled
with tiny holes to guide the dentist through surgery. Once the
patient is in the chair, the doctor can affix a set of new chompers in
about an hour.” There are 75 dentists doing the procedure now,
but Nobel expects to quickly train more. The treatment is pricey,
$2,000 to $3,000 per implant, or some $60,000 for the whole
mouth. See Forbes, September 5, 2005, p. 103 and
www.nobelbiocare.com/global/en/default.htm?langdetect=en.
(10/19/05)
169. Low
Cost Medical Care in India
“Mr.
Beeney’s story is becoming increasingly common as Europeans and
Americans, looking for worldclass treatments at prices a fourth or
fifth of what they would be at home, are traveling to India” (New
York Times, April 7, 2005, p. C6). Also x-ray scan interpretations
and lab testing is being done at low cost in India. (9/28/05)
168. Growth of Wound-Care Market
|